Health

Cofepris approves reusable insulin pen and Mexico will be its first market

Cofepris grants a health registration to GO-PEN, the Danish reusable insulin pen, and Mexico will be its first market worldwide. What is still missing: price and date.

Pluma reutilizable de insulina GO-PEN junto a un frasco sobre mesa clínica

The Federal Commission for the Protection against Sanitary Risks (Cofepris) granted a health registration to GO-PEN, a reusable insulin pen from the Danish company GO-Pen ApS, and Mexico will be the first country where the device is sold, according to coverage published on November 3, 2026.

The market the device is entering is large. According to the Diabetes Atlas of the International Diabetes Federation cited by Milenio, 13.6 million adults between 20 and 79 years old were living with diabetes in Mexico in 2024, including undiagnosed cases. The company estimates that more than 20 million people worldwide still administer insulin with syringes. For a health operator, the relevant data point is not only the size of the population: the device separates the dosing unit, which is kept, from the reservoir, which is discarded, and that changes the recurring cost structure of treatment. Ole Kjerkegaard Nielsen, CEO and co-founder of GO-Pen, said the development aims to broaden administration options for those who still depend on traditional syringes.

GO-PEN works with a reusable dosing unit and a disposable reservoir that the user fills with insulin from a compatible vial; an integrated selector allows the prescribed dose to be chosen. Unlike pens that require specific cartridges, the design uses formulations already sold in vials, provided they are covered in local labeling. Exclusive import and distribution in Mexico were assigned to Grupo LYBB, according to Saludiario. Before the Mexican registration, the device obtained 510(k) authorization from the U.S. Food and Drug Administration on April 24, 2025, and CE class IIb marking in November of that year. The company did not specify the price or the start date of sales in the Mexican market.

The registration leaves two questions on the table for those who operate in health: at what price and through which channel the device will reach pharmacies and clinics, and whether the model of a reusable unit plus disposable reservoir reduces the patient's monthly spending compared with the disposable pens that already have coverage.

This article was written with the assistance of artificial intelligence from verified sources and reviewed by a human editor before publication.

Sources